Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease

BACKGROUND: Infliximab original has changed the natural history of inflammatory bowel diseases (IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the first Infliximab biosimilar into the European and Spanish markets. Currently switching drugs data i...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerra Veloz, María Fernanda, Argüelles-Arias, Federico, Castro Laria, Luisa, Maldonado Pérez, Belén, Benítez Roldan, Antonio, Perea Amarillo, Raúl, Merino Bohórquez, Vicente, Calleja, Miguel Angel, Caunedo Álvarez, Ángel, Vilches Arenas, Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295832/
https://www.ncbi.nlm.nih.gov/pubmed/30581277
http://dx.doi.org/10.3748/wjg.v24.i46.5288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295832/
https://www.ncbi.nlm.nih.gov/pubmed/30581277
http://dx.doi.org/10.3748/wjg.v24.i46.5288

Ejemplares similares